Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23660896 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL4725556 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL18746889 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL20129008 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL4777139 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL3690528 | 0.97 | — | — | |
| SCHEMBL4872445 | 0.89 | — | — | |
| SCHEMBL10081549 | 0.87 | RAB9A (0.31) | — | |
| SCHEMBL7934735 | 0.86 | SMPD1 (0.36) | SMPD1 | |
| SCHEMBL7934687 | 0.86 | SMPD1 (0.36) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113831232-B | Preparation method of (9Z, 11E) -9, 11-hexadecadienal | 信越化学工业株式会社 | 2024-04-09 | — | — | CN | disclosed |
| CN-112441895-B | Dialkoxy alkadienyne compound, preparation method thereof and preparation method of dialkoxy alkadienyne aldehyde compound | 信越化学工业株式会社 | 2024-01-23 | — | — | CN | disclosed |
| EP-3929173-B1 | PROCESS FOR PREPARING (9Z,11E)-9,11-HEXADECADIENAL | SHINETSU CHEMICAL CO (JP) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-11319271-B2 | Process for preparing (9Z,11E)-9,11-hexadecadienal | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-03 | — | — | US | disclosed |
| EP-3789376-B1 | DIALKOXYALKADIENYNE COMPOUND AND A PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING A DIENYNAL COMPOUND | SHINETSU CHEMICAL CO (JP) | 2022-03-23 | — | — | EP | disclosed |
| EP-3789375-B1 | PROCESS FOR PREPARING 4-PENTEN-2-YNAL | SHINETSU CHEMICAL CO (JP) | 2022-03-02 | — | — | EP | disclosed |
| US-20210403403-A1 | PROCESS FOR PREPARING (9Z,11E)-9,11-HEXADECADIENAL | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3929173-A1 | PROCESS FOR PREPARING (9Z,11E)-9,11-HEXADECADIENAL | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-12-29 | — | — | EP | disclosed |
| WO-2005080375-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182092-A1 | Crystalline form of a biphenyl compound | THERAVANCE, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005051946-A2 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| WO-2004074812-A2 | LIBRARY OF BIPHENYL DERIVATIVES USEFUL FOR IDENTIFYING COMPOUNDS HAVING BOTH BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074246-A2 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403403-A1 | PROCESS FOR PREPARING (9Z,11E)-9,11-HEXADECADIENAL | CYP2J2, DHRS9, DHCR7 | SMPD1 2210/4885 |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB1, ADRB2, ADRA2B | SMPD1 2478/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | SMPD1 776/4885 |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRA2B, ADRB2, ADRB1 | SMPD1 1227/4885 |
| US-20050182092-A1 | Crystalline form of a biphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC10A1, REN | SMPD1 1776/4885 |
| US-11319271-B2 | Process for preparing (9Z,11E)-9,11-hexadecadienal | CYP2J2, DHRS9, DHCR7 | SMPD1 2193/4885 |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | ADRA2C, ADRB2, AHR | SMPD1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.